4-Methylpyrazole - CAS 7554-65-6
Not Intended for Therapeutic Use. For research use only.
Product Name:
Catalog Number:
1H-Pyrazole, 4-methyl-;4-Methyl-1H-pyrazole;Fomepizole;Antizol;Fomepizol
CAS Number:
4-Methylpyrazole is a competitive inhibitor of alcohol dehydrogenase, which catalyzes metabolism of ethylene glycol and methanol to toxic metabolites. It is used as an antidote for ethylene glycol or methanol poisoning. It may be used alone or in combination with hemodialysis. It can prevent the formation of toxic alcohol metabolites that generate metabolic acidosis at 10 µM in monkeys. It also inhibits CYP2E1 activity. It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system.
Molecular Weight:
Molecular Formula:
Kilogram to ton
Quality Standard:
In-house standard
Canonical SMILES:
Chemical Structure
CAS 7554-65-6 4-Methylpyrazole

Related Products

CAS 370586-05-3 CID-797718

(CAS: 370586-05-3)

CAS 70553-45-6 NS 3763

NS 3763
(CAS: 70553-45-6)

NS 3763 is a non-competitive kainate receptor antagonist of GLUK5 subunit-containing receptors (IC(50) = 1.6 microM)) without disrupting GLU(K6) subtype (IC(50)...

(CAS: 352305-79-4)

CP-5068 is a synthetic bio-active chemical.

CAS 17692-31-8 Dropropizine

(CAS: 17692-31-8)

Dropropizine is a racemic non-opiate antitussive agent, it is used as a cough suppressant.Dropropizine exhibits antitussive activity in cats noticeably lower th...

(CAS: 1015474-32-4)

CC122 is a novel agent for DLBCL. It is an orally available pleiotropic pathway modulator. It has antitumor and immunomodulatory activity. It is used for the tr...

CAS 71720-56-4 Fenoprofen calcium hydrate

Fenoprofen calcium hydrate
(CAS: 71720-56-4)

Fenoprofen calcium hydrate is a non-steroidal anti-inflammatory drug (NSAID).

CAS 119793-66-7 Propionyl-L-Carnitine HCl

Propionyl-L-Carnitine HCl
(CAS: 119793-66-7)

The hydrochloride salt form of L-Propionylcarnitine which has been found to be related to mitochondrial metabolism so that could be used in the treatment deteri...

CAS 523-50-2 Isopsoralen

(CAS: 523-50-2)

Angelicin is a furanocoumarin isolated from P. corylifolia might be a potential new agent for prevention of inflammatory reactions.

CAS 308242-62-8 Remimazolam

(CAS: 308242-62-8)

Remimazolam, a benzodiazepine derivative, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, currently in Phase III clinical development for ...

CAS 73590-85-9 OMeprazole sulphide

OMeprazole sulphide
(CAS: 73590-85-9)

Omeprazole sulphide is a metabolite of Omeprazole. It is an intermediate used in the production of the gastric proton pump inhibitors, omeprazole and esomeprazo...

N-desmethyl Netupitant
(CAS: 290296-72-9)

N-desmethyl Netupitant is a metabolite of an antiemitic drug called Netupitant.

CAS 57644-54-9 Gastrodenol

(CAS: 57644-54-9)

Gastrodenol is a mineral that is used in treating ulcers and upset stomach.

CAS 4499-40-5 Oxtriphylline

(CAS: 4499-40-5)

Oxtriphylline is a cough medicine derived from xanthine used in the treatment for chronic asthma.

CAS 141993-70-6 Eldacimibe

(CAS: 141993-70-6)

Eldacimibe is a Sterol O-acyltransferase inhibitor originated by Wyeth. No development was reported for Atherosclerosis and Hypercholesterolaemia in USA.

CAS 1515856-92-4 XEN445

(CAS: 1515856-92-4)

XEN445 is a potent and selective endothelial lipase inhibitor with IC50 of 0.237 μM.

CAS 5534-95-2 Pentagastrin

(CAS: 5534-95-2)

Pentagastrin is a synthetic polypeptide used as a diagnostic aid for evaluation of gastric acid secretory function

CAS 56180-94-0 Acarbose

(CAS: 56180-94-0)

Acarbose is an inhibitor of intestinal alpha-glucosidase, used to treat type 2 diabetes mellitus.

CAS 126-17-0 Solasodine

(CAS: 126-17-0)

Solasodine is a neuroprotective antioxidant glycoalkaloid of Solanum species. Solasodine increases superoxide dismutase (SOD), catalase (CAT),and glutathione (G...

(CAS: 724741-75-7)

STF-31 is a selective glucose transporter GLUT1 inhibitor.

CAS 30544-47-9 Etofenamate

(CAS: 30544-47-9)

Medication used to alleviate joint and muscle pain.

Reference Reading

1.Ethanol and Acetaldehyde After Intraperitoneal Administration to Aldh2-Knockout Mice-Reflection in Blood and Brain Levels.
Jamal M1, Ameno K2, Tanaka N2, Ito A2, Takakura A2, Kumihashi M2, Kinoshita H2. Neurochem Res. 2015 Dec 8. [Epub ahead of print]
This paper reports, for the first time, on the analysis of ethanol (EtOH) and acetaldehyde (AcH) concentrations in the blood and brains of Aldh2-knockout (Aldh2-KO) and C57B6/6J (WT) mice. Animals were administrated EtOH (1.0, 2.0 or 4.0 g/kg) or 4-methylpyrazole (4-MP, 82 mg/kg) plus AcH (50, 100 or 200 mg/kg) intraperitoneally. During the blood tests, samples from the orbital sinus of the eye were collected. During the brain tests, dialysates were collected every 5 min (equal to a 15 µl sample) from the striatum using in vivo brain microdialysis. Samples were collected at 5, 10, 15, 20, 25, 30 and 60 min intervals post-EtOH and -AcH injection, and then analyzed by head-space GC. In the EtOH groups, high AcH levels were found in the blood and brains of Aldh2-KO mice, while only small traces of AcH were seen in the blood and brains of WT mice. No significant differences in EtOH levels were observed between the WT and the Aldh2-KO mice for either the EtOH dose.
2.Methanol Kinetics in Chronic Kidney Disease After Fomepizole: A Case Report.
Maskell KF1, Beckett S, Cumpston KL. Am J Ther. 2015 Dec 9. [Epub ahead of print]
Methanol is a common toxicant in the United States, especially from automotive products. Its kinetics have been described previously and typically involve little urinary excretion. We present a case of prolonged methanol half-life in a patient with chronic kidney disease. An 80-year-old male with a baseline glomerular filtration rate of 24 mL·min·1.73 m was transferred to our facility after unintentional methanol ingestion. The original facility had treated him with an oral ethanol load; upon arrival to our facility, he was immediately loaded with fomepizole. His initial serum methanol concentration was 66.1 mg/dL. After a risk/benefit discussion, we decided not to perform hemodialysis on the patient and he was treated with fomepizole and supportive care. After 6 days as an inpatient, the patient's methanol level had declined to 22 mg/dL, fomepizole was discontinued, and the patient was able to be discharged without apparent complications.
3.Mind the gap: a case of severe methanol intoxication.
Nazir S1, Melnick S1, Ansari S1, Kanneh HT2. BMJ Case Rep. 2016 Feb 25;2016. pii: bcr2015214272. doi: 10.1136/bcr-2015-214272.
We report a case of a 37-year-old woman with non-insulin-dependent diabetes on sitagliptin, an alcohol abuser who was brought unresponsive to the emergency department of our hospital. On arrival, the patient was intubated and mechanically ventilated due to a low Glasgow Coma score of 3/15. Initial laboratory testing identified profound high anion gap metabolic acidosis. Owing to the dubious circumstances and the depth of acidosis, methanol and ethylene glycol intoxication was suspected. Further evaluation revealed a significantly increased serum osmolal gap. Pending volatile compound screen, fomepizole was started and urgent haemodialysis undertaken. Subsequent brain MRI identified changes in putamen of bilateral basal ganglia, suggestive of methanol intoxication. The patient was later found to have an initial methanol level of 237 mg/dL. She was successfully extubated on day 2 of hospitalisation, with residual cognitive and visual deficits.
4.[Antidote update].
Kiyota K. Nihon Rinsho. 2016 Feb;74(2):236-40.
In Japan, several products of the antidote for poisoning have been authorized in clinical use from some recent years. For example, Hydroxcobalamin for cyanide poisoning was introduced in 2008. In 2009, Ministry of Health, Labour and Welfare invited suggestions of demand of pharmaceutical products which is high in the need in the medical care but yet unauthorized. Japanese Society for Clinical Toxicology and Japan Poison Information Center applied some candidates including methyleneblue (MB) and fomepizole, both of them were authorized in clinical market in 2015. MB is the medicine for methemoglobinemia, caused by variety of chemical products such as nitrogen oxide. Fomepizole is the antidote for methanol and ethyleneglycol, blocking alcohol dehydrogenase.